Compare TZOO & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TZOO | RFL |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 63.5M |
| IPO Year | 2003 | 2017 |
| Metric | TZOO | RFL |
|---|---|---|
| Price | $6.20 | $1.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 99.7K | 57.2K |
| Earning Date | 04-28-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $10.57 | N/A |
| Revenue Next Year | $9.35 | N/A |
| P/E Ratio | $14.44 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $4.72 | $1.12 |
| 52 Week High | $16.56 | $3.19 |
| Indicator | TZOO | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 48.29 |
| Support Level | $5.45 | $1.15 |
| Resistance Level | $7.31 | $1.32 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 64.10 | 31.66 |
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.